Dupixent Lawsuit

Cancer Risk Allegations, Legal Status, and What Patients Need to Know

Last updated: May 2026  |  Drug: Dupixent (dupilumab)  |  Manufacturers: Sanofi & Regeneron  |  Read time: ~12 min

Dupixent (dupilumab) was, by almost any clinical measure, one of the most significant advances in dermatology and immunology in the past decade. For patients with moderate-to-severe atopic dermatitis who had exhausted topical therapies, it offered meaningful, sometimes dramatic relief from a condition that had profoundly affected their daily lives. For those with certain types of asthma and chronic sinusitis, it similarly expanded the available treatment options in conditions that had been difficult to manage. Its commercial success — generating billions of dollars annually for its manufacturers Sanofi and Regeneron — reflected genuine clinical value.

But as the drug’s use expanded across millions of patients and multiple indications, a troubling pattern began to emerge in the adverse event data: a potential association between Dupixent use and cutaneous T-cell lymphoma (CTCL), a rare but serious and potentially fatal blood cancer. Scientific research has since strengthened the signal. The FDA has taken notice. And patients who developed cancer after using the drug — in some cases at ages younger than would typically be expected for this cancer — have begun filing lawsuits.

This page explains what Dupixent is, what the lawsuits allege, what the scientific evidence shows, the current state of the litigation, and what patients and families need to know if they believe they may have a claim.

What Is Dupixent and How Does It Work?

Dupixent (dupilumab) is a biologic medication manufactured jointly by Sanofi and Regeneron Pharmaceuticals. It is a monoclonal antibody — a laboratory-engineered protein designed to block specific components of the immune system’s inflammatory signaling cascade. Specifically, Dupixent inhibits the signaling pathways of two proteins, interleukin-4 (IL-4) and interleukin-13 (IL-13), which play a central role in the type 2 inflammatory response that drives conditions like atopic dermatitis and certain forms of asthma.

The drug’s FDA approval history reflects its progressively expanded role in treating inflammatory conditions. The key regulatory milestones include:

• March 2017: Initial FDA approval for adults with moderate-to-severe atopic dermatitis (eczema) not adequately controlled by topical therapies
• October 2018: Approval expanded to include add-on maintenance treatment for adults with moderate-to-severe asthma
• March 2019: Label expanded to include adolescents aged 12 to 17 with atopic dermatitis
• Subsequent approvals: Chronic rhinosinusitis with nasal polyps, eosinophilic esophagitis, prurigo nodularis, and additional pediatric indications

By the early 2020s, Dupixent had become one of the fastest-growing biologic drugs in the world, with tens of millions of prescriptions written globally. Its rapid expansion across multiple indications and age groups means that the patient population potentially affected by the safety concerns now in litigation is substantial.

What the Lawsuits Allege: Failure to Warn About Cancer Risk

The legal theory at the center of Dupixent litigation is a familiar one in pharmaceutical mass tort law: failure to warn. Plaintiffs allege that Sanofi and Regeneron knew — or had strong reason to know — that Dupixent was associated with an elevated risk of cutaneous T-cell lymphoma and related cancers, and that they failed to disclose that risk to patients and their physicians through the drug’s labeling and marketing communications.

This theory has particular legal force in the Dupixent context for a reason that goes beyond the elevated risk itself: CTCL is a cancer that can closely mimic atopic dermatitis in its early presentation. Patients who were being treated with Dupixent for what appeared to be a worsening skin condition may, in fact, have been experiencing early or progressing CTCL that was simultaneously masked by the drug’s anti-inflammatory effects. The lawsuits allege that this risk — both the elevated incidence of CTCL in Dupixent users and the drug’s potential to obscure early cancer symptoms — was never communicated to patients.

The specific legal claims most commonly advanced in Dupixent lawsuits include the following:

Failure to Warn

The central allegation: Sanofi and Regeneron had access to adverse event data, scientific literature, and post-market surveillance information that should have prompted label updates warning patients and physicians of the CTCL association. The drug’s label, as of early 2026, still does not warn of cancer risk — a fact that plaintiffs’ attorneys point to as evidence that the manufacturers have consistently chosen not to act on the available safety signal.

Negligence

Plaintiffs allege that the manufacturers failed to adequately monitor post-market adverse event reports, failed to conduct or commission research that would have clarified the cancer risk, and failed to respond appropriately once the signal became apparent in the scientific literature and regulatory databases.

Misrepresentation and False Marketing

Several complaints allege that Sanofi and Regeneron actively marketed Dupixent as a safe and well-tolerated therapy without adequately disclosing the cancer risk — and that marketing communications created a false impression of the drug’s safety profile that influenced both prescribing decisions and patients’ informed consent.

As of May 2026, the FDA-approved Dupixent label does not contain a warning about the risk of cutaneous T-cell lymphoma or any other cancer. Plaintiffs argue that this omission — maintained despite growing scientific evidence and FDA scrutiny — is itself evidence of the manufacturers’ failure to meet their duty to warn.

Understanding Cutaneous T-Cell Lymphoma (CTCL)

The gravity of the Dupixent lawsuits cannot be fully appreciated without understanding what cutaneous T-cell lymphoma is — and why its potential association with a widely prescribed skin condition drug is so clinically and legally significant.

CTCL is a category of non-Hodgkin lymphoma in which malignant T-cells — a type of white blood cell that plays a central role in immune function — accumulate in the skin. It is not a single disease but an umbrella term for several related lymphoma subtypes, the most common of which are mycosis fungoides and Sézary syndrome. The disease typically has an indolent early course — progressing slowly over months or years — but can advance to aggressive systemic disease in its later stages.

Why CTCL Is Particularly Dangerous in the Dupixent Context

What makes CTCL especially concerning for Dupixent patients is the degree to which its early symptoms can be clinically indistinguishable from atopic dermatitis. In its early stages, CTCL typically presents as persistent, scaly, or red patches and plaques on the skin — the same presentation that leads patients to seek treatment for eczema in the first place. A physician managing a patient with apparently worsening atopic dermatitis and prescribing Dupixent may, in fact, be treating undiagnosed CTCL. The drug’s immunosuppressive mechanism may simultaneously mask the visible cancer signs while the malignancy progresses.

This diagnostic overlap is not a hypothetical concern — it is documented in the medical literature and is central to the plaintiffs’ case. The warning signs of CTCL that patients and caregivers should be aware of include:

• Persistent red, scaly patches or plaques that do not respond to standard treatment
• New or worsening skin lesions that look or feel different from typical eczema flares
• Skin thickening or tumor-like growths in affected areas
• Swollen lymph nodes, particularly in the neck, armpits, or groin
• Unexplained fatigue or unintentional weight loss
• Joint pain or swelling without another clear cause

Any patient currently taking Dupixent who develops new or atypical skin changes — particularly changes that are not responding to treatment as expected — should discuss the possibility of a specialist dermatology evaluation with their physician. A skin biopsy is the definitive diagnostic tool for CTCL.

What the Scientific Evidence Shows

The legal claims against Sanofi and Regeneron are grounded in a growing body of peer-reviewed research. The science is not conclusive in the sense of establishing definitive causation — clinical research of this kind rarely is at this stage of a drug’s post-market history — but the signal is consistent and, by the standards applied in pharmaceutical litigation, substantial.

Retrospective Study: Elevated CTCL Risk in Dupixent Users

A study published in Dermatologic Therapy examined two matched groups totaling 19,612 patients with atopic dermatitis. Patients in the Dupixent-treated cohort were 4.59 times more likely to receive a CTCL diagnosis than those in the non-Dupixent group. This level of elevated risk — approaching fivefold — represents a clinically significant finding, particularly given the rarity of CTCL in the general population and the size of the patient cohorts involved.

Harvard Research: Elevated Lymphoma Risk in Asthma Patients

A 2025 study conducted by Harvard researchers and focused specifically on asthma patients found that those treated with Dupixent had a statistically significant elevated risk of lymphoma — more than five times higher than comparable patients not on the drug. The elevated risk included both CTCL and peripheral T-cell lymphoma, suggesting that the association is not confined to patients with atopic dermatitis and may reflect a broader class-level mechanism.

Age at Diagnosis: A Particularly Concerning Signal

Among the findings in the available data, the pattern of diagnosis timing is one of the most striking. In one study cohort, all eczema patients in the non-Dupixent control group were over 60 years old when diagnosed with CTCL — consistent with CTCL’s typical presentation as a disease of older adults. In the Dupixent-treated group, only half of patients were 60 or older at diagnosis. The implication — that Dupixent use may be associated with CTCL occurring in meaningfully younger patients — is a serious finding that would suggest the drug is not merely failing to protect against a background risk but may be accelerating or enabling cancer in patients who would otherwise not have developed it at that age.

Proposed Biological Mechanisms

Researchers have proposed several biological pathways through which Dupixent’s mechanism of action might contribute to the observed elevated CTCL risk. None has yet been definitively established, but the consistency of the research findings across different study populations and designs provides the foundation that plaintiffs’ expert witnesses will develop in litigation. The leading hypotheses include:

• Immune surveillance impairment: by blocking IL-4 and IL-13 signaling pathways, Dupixent may reduce the immune system’s capacity to identify and destroy early malignant T-cells before they establish a foothold in the skin
• The unmasking or masking effect: the drug’s anti-inflammatory action may suppress the visible skin manifestations of early CTCL — temporarily reducing redness and scaling — while the underlying malignancy progresses undetected
• Malignant T-cell stimulation: some researchers have proposed that IL-13 signaling, redirected by Dupixent’s blocking mechanism, may interact with receptors overexpressed on cancerous T-cells in ways that promote their growth

The FDA’s Response and the Label Omission

Federal regulators have not been unaware of the emerging safety signal. In March 2025, the FDA added Dupixent to a watch list of medications under review for potentially serious risks, citing the accumulating reports of CTCL in Dupixent users. The agency stated that it was evaluating the available data to determine whether regulatory action was warranted.

The FDA’s Adverse Event Reporting System (FAERS) — the agency’s voluntary adverse event database — contains nearly 300 reports of lymphoma among Dupixent users as of early 2026. Of those, 138 cases involve cutaneous T-cell lymphoma, with additional reports of Sézary syndrome and other T-cell lymphoma subtypes. Safety surveillance experts consistently note that FAERS data captures only a small fraction of actual adverse events — estimates range from 1 to 10 percent of true incidence — meaning the underlying case count is very likely substantially higher than the reported figures suggest.

Despite the regulatory scrutiny and the accumulating adverse event data, the Dupixent label has not been updated to reflect the cancer risk. As of May 2026, the drug’s FDA-approved prescribing information discloses side effects including conjunctivitis, keratitis, injection site reactions, and hypersensitivity reactions. There is no warning about CTCL, lymphoma, or any other malignancy. For plaintiffs’ attorneys, this label omission is not just a background fact — it is the evidentiary foundation of the failure-to-warn claim.

Key Legal Developments: Litigation Timeline

The Dupixent litigation is moving quickly relative to the typical pace of pharmaceutical mass tort proceedings. The first cases were filed in late 2025, and case counts are growing steadily as awareness of the CTCL association reaches more patients and plaintiff attorneys. The following timeline documents the significant legal milestones to date.

 

October 2025 — The first Dupixent wrongful death lawsuit was filed. The case involves a Tennessee woman who died from T-cell lymphoma within months of beginning Dupixent injections, making this the first fatality alleged to be connected to Dupixent use to enter formal litigation.

November 2025 — The first Dupixent T-cell lymphoma lawsuit advanced into early court proceedings, with attorneys appearing before Magistrate Judge Alistair Newbern for an initial case management conference. This marks the beginning of the judicial process for the litigation.

December 2025 — A woman filed suit in Illinois alleging that her CTCL diagnosis was linked to Dupixent injections she received between July 2017 and February 2018. The complaint alleges that Sanofi and Regeneron falsely marketed the drug as safe and failed to disclose the cancer association.

January 2026 — A Florida man filed suit alleging he developed cutaneous T-cell lymphoma following Dupixent use for atopic dermatitis. The complaint alleges the defendants were aware of the link between the drug and CTCL and failed to warn patients or their physicians.

February 2026 — Plaintiffs’ attorneys filed a motion to transfer related Dupixent cases to the United States District Court for the Northern District of Georgia, noting that more than 25 percent of all Dupixent cancer lawsuits filed to date are already pending there. This motion signals the early stages of what is likely to become a formal consolidation proceeding.

May 2026 — No multidistrict litigation has yet been formally established, though legal analysts broadly expect an MDL petition to be filed as case counts continue to rise. The litigation is in its early stages, with discovery, expert development, and any bellwether trial selection still ahead.

 

The motion to consolidate cases in the Northern District of Georgia is a significant marker. The arguments made in that motion — that the cases share common questions of fact and that consolidation would serve efficiency and consistency — are precisely the arguments that typically support an MDL petition before the Judicial Panel on Multidistrict Litigation. Whether formal MDL consolidation follows, and where such an MDL might be centralized, will be among the most consequential early procedural developments in this litigation.

Who May Be Eligible to File a Dupixent Lawsuit?

Dupixent lawsuits are individual personal injury or wrongful death claims. There is no class action. Each plaintiff’s case is evaluated on its own medical history, diagnosis timeline, and documentary record. That said, the eligibility framework that attorneys are currently applying to evaluate potential Dupixent claims follows a recognizable structure drawn from the pharmaceutical mass tort model.

Patients and families who may have a viable claim generally need to satisfy the following core criteria:

Confirmed Dupixent Use

Prescription records, pharmacy records, infusion center records, or insurance records documenting that the patient was prescribed and received dupilumab (Dupixent) at some point during their treatment history.

A Qualifying Cancer Diagnosis

A subsequent diagnosis of cutaneous T-cell lymphoma (including mycosis fungoides), Sézary syndrome, peripheral T-cell lymphoma, or another T-cell or NK-cell lymphoma. Attorneys evaluating these cases will want to see pathology reports, biopsy results, oncology records, and any available staging documentation. The specificity and objective documentation of the cancer diagnosis — as opposed to a clinical impression alone — is important for establishing a strong claim.

Temporal Connection

The cancer diagnosis should have occurred during or following the period of Dupixent use, with a timeline that plausibly supports a connection between the two. The research suggesting earlier-than-expected diagnosis in Dupixent-treated patients is relevant here: a CTCL diagnosis in a patient significantly younger than the typical presentation age, occurring during or after Dupixent use, is a particularly compelling factual profile.

Statute of Limitations

Personal injury claims are subject to statutes of limitations that vary by state, typically running two to four years from the date of injury or from the date the plaintiff knew or reasonably should have known that their injury was connected to the drug. For cancer diagnoses made before widespread awareness of the Dupixent-CTCL association, the discovery rule may extend the filing window. Patients should not assume they are outside the limitations period without first consulting an attorney, as the specific facts of each case can materially affect the applicable deadline.

If you took Dupixent and subsequently received a diagnosis of cutaneous T-cell lymphoma or a related T-cell cancer, do not assume the window to file has closed. The discovery rule may apply, and an attorney can assess the specific timeline relevant to your state and circumstances.

What Compensation May Be Available?

No settlements have been reached in Dupixent litigation as of May 2026. The cases are in their earliest stages, with the formal litigation process — discovery, expert witness development, and any bellwether trial selection — still ahead. Projecting settlement values at this stage would be premature and potentially misleading.

What can be described with confidence is the range of damages that plaintiffs in pharmaceutical personal injury litigation typically pursue and that courts have historically awarded in comparable cases. In Dupixent lawsuits, plaintiffs may seek compensation for the following categories of harm:

• Medical expenses: all costs associated with the cancer diagnosis and treatment, including oncologist fees, biopsy and pathology costs, chemotherapy, radiation, immunotherapy, hospitalization, and ongoing specialist care
• Lost wages and diminished earning capacity: income lost during treatment and recovery, and where cancer has caused permanent disability or shortened working life, the present value of lost future earning capacity
• Pain and suffering: compensation for the physical pain and emotional distress attributable to both the cancer and the delayed or missed diagnosis that may have resulted from Dupixent’s masking of early CTCL symptoms
• Loss of enjoyment of life: damages for the ways in which a cancer diagnosis has permanently altered the plaintiff’s ability to participate in activities and relationships that were part of their life before the illness
• Wrongful death damages: in cases where a patient has died from CTCL following Dupixent use, surviving family members may be entitled to pursue wrongful death claims, including damages for loss of companionship, funeral and estate expenses, and the economic value of the deceased’s future contributions

 

The strength of an individual plaintiff’s case will depend on the quality of medical documentation, the severity and progression of the cancer, the age of the patient at diagnosis, and the degree to which expert testimony can establish a causal connection between Dupixent use and the cancer outcome. Cases involving younger patients, more aggressive cancer progression, significant medical costs, or documented delayed diagnosis due to the eczema-CTCL overlap are generally expected to command higher case values.

What Patients and Families Should Do Now

If you are currently taking Dupixent and are concerned about the CTCL association, the most important immediate step is to speak with your prescribing physician before making any changes to your treatment. Stopping a biologic medication abruptly without medical guidance can cause an eczema flare or worsen the underlying condition it was prescribed to manage. Your physician can assess your individual risk profile, review your skin for any changes that warrant further evaluation, and advise on whether specialist referral is appropriate.

If you or a family member took Dupixent and subsequently received a cancer diagnosis, the steps that matter most from both a medical and legal standpoint are:

Gather and Preserve Your Medical Records

This includes all prescription records documenting Dupixent use, pharmacy dispensing records, any prior eczema or dermatitis treatment history, dermatology consultation notes, pathology and biopsy reports confirming the cancer diagnosis, oncology treatment records, and hospital or infusion center records. The completeness of this documentation is the foundation of any legal claim. Do not assume records are being preserved automatically — request copies and store them securely.

Seek a Specialist Dermatology Evaluation

If you have experienced persistent or atypical skin changes during or after Dupixent use that have not been fully evaluated by a dermatologist, requesting a specialist consultation is important both for your health and for establishing the medical record relevant to any legal claim. A skin biopsy is the definitive tool for diagnosing or ruling out CTCL, and the results of that biopsy will be among the most important documents in any subsequent litigation.

Consult a Qualified Pharmaceutical Litigation Attorney

Most law firms handling Dupixent cases work on a contingency basis, meaning there are no upfront costs and the attorney collects a fee only if they recover compensation for you. An initial case review is typically free and takes no more than 30 to 45 minutes. An experienced pharmaceutical litigation attorney can assess whether the timeline and facts of your case meet the current standards being applied to Dupixent claims, advise on any applicable statute of limitations concerns, and explain what the litigation process would involve.

Act Within the Statute of Limitations

Statutes of limitations for personal injury claims vary by state but typically run two to four years from the date of injury or discovery. Missing this deadline permanently eliminates the right to sue, regardless of how strong the underlying claim might otherwise be. Do not assume you are within the window or outside it without speaking to an attorney who can assess the specific facts of your case and the law of your jurisdiction.

Key Takeaways

For patients, families, and legal professionals following the Dupixent litigation, the following points summarize the current state of the evidence and the proceedings:

• Dupixent (dupilumab), manufactured by Sanofi and Regeneron, has been associated in multiple peer-reviewed studies with an elevated risk of cutaneous T-cell lymphoma, with one study reporting a nearly fivefold increased risk in Dupixent-treated atopic dermatitis patients
• The drug’s label does not, as of May 2026, contain any warning about CTCL or lymphoma — despite FDA scrutiny and nearly 300 adverse event reports in the FAERS database
• The clinical overlap between early CTCL and atopic dermatitis, combined with Dupixent’s potential to mask early cancer symptoms, means some patients may have experienced delayed diagnosis of a potentially serious cancer
• Lawsuits are being filed across multiple states, with early consolidation proceedings underway; no formal MDL has been established as of May 2026, but legal analysts broadly anticipate one
• Eligible plaintiffs are those who took Dupixent and subsequently received a diagnosis of CTCL, Sézary syndrome, peripheral T-cell lymphoma, or related cancer, within the applicable statute of limitations
• No settlements have been reached; the litigation is in its early stages with discovery and bellwether trial processes ahead

The Dupixent lawsuits represent patients exercising their fundamental right to hold pharmaceutical manufacturers accountable when known or knowable risks are not disclosed. For patients who accepted the risks described on a drug’s label — and who were never told that cancer was among them — the litigation offers a legal forum for seeking answers and compensation.